A Bengaluru laboratory has produced something the global antibiotic market has struggled to price: an agent that makes existing antibiotics work again without adding to resistance. The science is published. The commercial question is entirely open.
On 25 August 2026 the Indian Institute of Science announced work published in npj Biofilms and Microbiomes as “A matrix-targeting enzyme and an engineered bioactive gauze enable resistance-agnostic antibiofilm wound care”, DOI 10.1038/s41522-026-01115-3. First author Reshma Ramakrishnan, corresponding authors Debasis Das of the Department of Inorganic and Physical Chemistry and Dipshikha Chakravortty of Microbiology and Cell Biology, with Kirti Parmar, Velpandi Ramachandran, Debmitra Sen and Raju S Rajmani.
The target is Acinetobacter baumannii, a hospital pathogen on the World Health Organization’s critical priority list, and the mechanism is what makes this commercially unusual. A. baumannii shelters inside a biofilm — a self-built matrix of sugars, proteins, fats and free DNA that keeps antibiotics and immune cells out. Between forty-five and ninety-five per cent of that matrix is polysaccharide. The team searched genomic data from bovine rumen microbes, whose working life is spent digesting cellulose, for an enzyme that could cut those sugar chains. The one that worked has been named CRhAB, and it acts on Klebsiella pneumoniae biofilms as well — two of the six ESKAPE pathogens, one enzyme.
CRhAB — the translation position
| Metric / Provision | Details |
|---|---|
| Institution | Indian Institute of Science, Bengaluru |
| Published | npj Biofilms and Microbiomes, 2026 |
| DOI | 10.1038/s41522-026-01115-3 |
| Announced | 25 August 2026 |
| Mechanism | Strips the biofilm matrix; does not kill |
| Consequence | Applies no selection pressure for resistance |
| Format demonstrated | Enzyme-immobilised medical gauze |
| Evidence stage | Mouse wound infection model |
| Human data | None |
| Funder named in the announcement | None |
| Patent or licence position stated | None |
Source: IISc press release of 25 August 2026 and the cited paper. Compiled by Blitz India. Photograph note: the institute’s images of the team and the gauze are credited to IISc photographers and are not copyright-free. Under Circular BIMG/CIR/2026/02 no agency or uncleared picture runs, and this in-house data card takes its place.
Why the mechanism changes the economics
Every antibiotic on the market carries a commercial contradiction. It works, it is prescribed, and the prescribing breeds the resistance that eventually retires it. That is why the antibiotic pipeline has thinned: a drug whose useful life shortens with every course sold is difficult to build a business case around, and public money has had to step in repeatedly to keep discovery going.
CRhAB sits outside that logic. It does not kill the organism; it removes the organism’s shelter. In the words of the first author: “Instead of directly killing the bacteria, it weakens their defenses, potentially restoring the effectiveness of existing antibiotics while reducing the selective pressure that drives antibiotic resistance.” The paper’s own term for this is resistance-agnostic. An agent whose usefulness does not erode with use has a materially different value curve from an antibiotic, and it also has a different customer — it makes cheap generic antibiotics that hospitals already stock work again, rather than replacing them.
What has actually been demonstrated, and what has not
Investors and licensing offices should read the stage carefully. The team immobilised the enzyme in a gauze and tested it on infected wounds in mice. There is no human trial and no clinical result. Work continues on a patch-style dressing aimed at diabetic foot infection, on delivery for respiratory infection, and on combining enzymes to widen the range of biofilms addressed, with a stated long-term goal of an inhalable or nebulisable formulation. All of that is intention, and it should be reported as such.
Two commercial facts are simply absent from the announcement and should not be inferred. No funding agency is named. No patent or licensing position is stated. Neither omission is unusual for an academic release; both are material to anyone assessing this, and both are questions for the institute’s intellectual property and technology transfer cell rather than matters for guesswork.
The market this would enter
The addressable clinical territory in India is not niche. Diabetic foot infection, ventilator-associated pneumonia and chronic non-healing wounds are large and growing burdens on Indian tertiary care, and each is a setting where biofilms are the reason treatment fails rather than an incidental complication. A dressing, unlike a systemic drug, also reaches district hospitals without cold-chain heroics if the enzyme can be made stable at Indian ambient temperatures — which is precisely the question the next phase has to answer.
The obstacles to scaling are the ordinary ones, and they are where Indian laboratory work has historically been lost: enzyme stability and shelf life, cost of production at scale, toxicology, and a regulatory pathway for a product that is legally a combination of a biological agent and a device rather than a drug. None of it is research. All of it is capital.
A translational package covering stability, toxicology and pilot manufacture — funded through the Indian Council of Medical Research, the Department of Biotechnology or BIRAC, and tied to a named tertiary-care partner for a first-in-human wound study — would carry this across the gap. So would an early, public statement of the patent position, because the licensing decision taken in the next year determines whether the manufacturing value stays in India. The discovery has been made here. Whether the product is made here is a decision, not an outcome.